Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Smoldering Multiple Myeloma in Latin America- Risk Stratification

Blood (2024) 144 (Supplement 1): 3774.

https://doi.org/10.1182/blood-2024-209038

Published: 2024

Journal Articles

Daratumumab-Based Quadruplet Versus Triplet Induction Regimens in Frontline Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Joao Tadeu Damian Souto Filho, Lucas Oliveira Cantadori, Edvan De Queiroz Crusoe, Vania Hungria, Angelo Maiolino

Blood (2024) 144 (Supplement 1): 258.

https://doi.org/10.1182/blood-2024-202677

Published: 2024

Journal Articles

Real World Evidence- the Proportion of Myeloma Patients' Death Due to Early Progression

Blood (2023) 142 (Supplement 1): 3789.

https://doi.org/10.1182/blood-2023-187790

Published: 2023

Journal Articles

Variability in End-of-Life Care and Perception of Palliative Care Among Physicians in the Hematology Unit of a Reference Service in the State of Bahia, Brazil

Diego Lopes Paim Miranda, Alini Maria Orathes Ponte Silva, Lais T. Silva, Marianna Batista Vieira Lima, Monica Botura, Edvan De Queiroz Crusoe, Marco Aurelio Salvino

Blood (2022) 140 (Supplement 1): 13295–13296.

https://doi.org/10.1182/blood-2022-170627

Published: 2022

Journal Articles

Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS

Edvan De Queiroz Crusoe, Joanna Leal, Juliana Andrade Santos, Herbert Henrique de Melo Santos, Allan de souza Santos, Larissa Ferreira Lucas, Alessandro de M. Almeida, Marcos Chaves, Daniela Dourado Dutra, Vania T.M. Hungria, Marco Aurelio Salvino, Maria da Gloria B. Arruda

Blood (2022) 140 (Supplement 1): 7699–7700.

https://doi.org/10.1182/blood-2022-164866

Published: 2022

Journal Articles

Evaluation of Hematopoietic Stem Cell Product As a New Site for Minimal Residual Disease By Next Generation Flow in Multiple Myeloma

Herbert Henrique de Melo Santos, Glaciano Ribeiro, Allan de souza Santos, Marcos Chaves, Joanna Leal, Juliana Andrade Santos, Alessandro de M. Almeida, Marco Aurelio Salvino, Mariane Melo Santos, Vania Hungria, Maria da Gloria B. Arruda, Edvan De Queiroz Crusoe

Blood (2021) 138 (Supplement 1): 4927.

https://doi.org/10.1182/blood-2021-154129

Published: 2021

Journal Articles

COVID-19 in Multiple Myeloma Patients: Frequencies and Risk Factors for Hospitalization, Ventilatory Support, Intensive Care Admission and Mortality -Cooperative Registry from Grupo Brasileiro De Mieloma Multiplo (GBRAM)

Marcia Garnica, Edvan De Queiroz Crusoe, Glaciano Ribeiro, Rosane Bittencourt, Roberto José Pessoa Magalhães, Karla Richter Zanella, Abrahão Elias Hallack Neto, Juliana Lima, Caroline Sola, Emmanuella G Souza, Andre Magalhaes, Angelo Maiolino, Vania Hungria

Blood (2021) 138 (Supplement 1): 4104.

https://doi.org/10.1182/blood-2021-153629

Published: 2021

Journal Articles

Progression Free Survival (PFS) Analysis of Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients

Edvan De Queiroz Crusoe, Joanna Leal, Marco Aurelio Salvino, Larissa Ferreira Lucas, Juliana Andrade Santos, Herbert Henrique de Melo Santos, Alessandro de M. Almeida, Allan de souza Santos, Marcos Chaves, Mariane Melo Santos, Sarah Queiroz Silva, Lucas de Oliveira Vieira, Cleverson Alves Fonseca, Elisangela Adorno, Vania Hungria, Maria da Gloria B. Arruda

Blood (2021) 138 (Supplement 1): 3943.

https://doi.org/10.1182/blood-2021-150607

Published: 2021

Journal Articles

First Description of Upfront Target Therapy Treating AML and Bcll Presented Simultaneously As First Line

Juliana Santos Carvalho, MD, Anna Flávia Silva Alves Silva, MD, Maysa Coité Silva, MD, Itala Gomes Santos, MD, Laryssa Pinto Aragão, MD, Larissa Ferreira Lucas, MD, Herbert Henrique de Melo Santos, MD, Mônica Botura, MD, Alex Nano Magalhães Rêgo, MD, Maria da Gloria B. Arruda, MD PhD, Edvan De Queiroz Crusoe, MDPhD, Alessandro de M. Almeida, MD, Renata Alves, MD, Marianna Batista Vieira Lima, MD, Victor Oliveira Sousa Guimarães, MD, Marco Aurelio Salvino, MD PhD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-143224

Published: 2020

Journal Articles

Immune Profiling Evaluation of Newly Diagnose Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients Treated with Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone. Preliminary Results

Allan de souza Santos, BS, Herbert Henrique de Melo Santos, MD, Marco Aurelio Salvino, MD PhD, Sarah Queiroz Silva, MD, Larissa Ferreira Lucas, MD, Alessandro de M. Almeida, MD, Mariane Melo Santos, BS, MsC, Juliana Andrade Santos, MD, Vania T. M. Hungria, MD PhD, Maria da Gloria B. Arruda, MD PhD, Alex Torres, PhD, Edvan De Queiroz Crusoe, MDPhD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-141438

Published: 2020

Journal Articles

Brazilian Real-World Multiple Myeloma (MM) Electronic Platform Register Project

Edvan De Queiroz Crusoe, MDPhD, Glaciano Ribeiro, MD, Karla Richter Zanella, MD, Leila Martins Perobelli, MD, Milton A. F. Aranha, MD, Marcelo Capra, MD PhD, Roberto José Pessoa Magalhães, MD, James Maciel, Rosane Bittencourt, MD, Emanuella Souza, Rafael Dezen Gaiolla, PhDMD, Walter Braga, MD, Fabiana Higashi, MD, Gracia Martinez, MD PhD, Abrahão Elias Hallack Neto, MD PhD, Danielle Leao Cordeiro De Farias, MDMSc,MBA, Virgilio Costa Farnese, MD, Nelson S Castro, MD, Renato Tavares, MD, Jacqueline Holanda De Souza, MD, Jandey Glória Bigonha, MD, Ederson Roberto Mattos, MD, Caroline Sola, MD, Joao Tadeu Souto Filho, MDPhD, LUiza da Silva, MD, Cleder Aparecido Da Silva Da Silva Araujo, MD, Jorge Vaz Pinto Neto, MD, Emanuel Silva, MD, Nelson Hamerschlak, MD PhD, Fabio Moore Nucci, MDPhD, Eduardo Flavio Oliveira Ribeiro, MD, Rafael Cunha, MD, Andre H Crepaldi, MD, Manuella Sampaio Almeida, MD, Gislaine B O Duarte, MD, Andre Magalhaes, MD, Dani Laks, MD PhD, Marcos Daniel, MD, Angelo Maiolino, MD, Vania T. M. Hungria, MD PhD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-142072

Published: 2020

Journal Articles

Preliminary Results of Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Newly Diagnosed Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients

Edvan De Queiroz Crusoe, MDPhD, Marco Aurelio Salvino, MD PhD, Sarah Queiroz Silva, MD, Herbert Henrique de Melo Santos, MD, Allan de souza Santos, BS, Alessandro de M. Almeida, MD, Lucas de Oliveira Vieira, MD, Cleverson Alves Fonseca, Pham, Larissa Ferreira Lucas, MD, Joanna Leal, MD, Mariane Melo Santos, BS, MsC, Juliana Andrade Santos, MD, Elisangela Adorno, Pham, PhD, Vania T. M. Hungria, MD PhD, Maria da Gloria B. Arruda, MD PhD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-138873

Published: 2020

Journal Articles

Superiority of Triple Combination Bortezomib + Cyclophosphamide and Dexamethasone (VCD) Versus Thalidomide + Cyclophosphamide and Dexamethasone (CTD) in Newly Diagnosed Multiple Myeloma Transplant-Eligible Patients

Blood (2017) 130 (Supplement 1): 5527.

https://doi.org/10.1182/blood.V130.Suppl_1.5527.5527

Published: 2017

Journal Articles

Combined Analysis of 3,664 Patients with Multiple Myeloma (MM) from Latin America (LA) and Asia

Blood (2017) 130 (Supplement 1): 5386.

https://doi.org/10.1182/blood.V130.Suppl_1.5386.5386

Published: 2017

Journal Articles

Prevalence of Oligoclonal Bands in Multiple Myeloma Patients Who Achieved Better Results Than Very Good Partial Response after Treatment with Standard or High Doses Chemotherapy-Final Analysis

Luiza soares Vieira, MD, Edvan de queiroz Crusoe, MD MsC, Manuella de S. Sampaio Almeida, MD PhD, Lais Sousa, MD, ana Lucia Perez, MD, Priscilla Cury, MD, Marina Rossato, MD, Fabiana Higashi, MD, ana Luiza Dias, MD, anna Carolina Castro, MD, Carlos Chiattone, MD PhD, Vania T M Hungria, MDPhD

Blood (2015) 126 (23): 4210.

https://doi.org/10.1182/blood.V126.23.4210.4210

Published: 2015

Journal Articles

Comparison of Kappa & Lambda Freelite to Total Kappa & Lambda Immunoassays for the Detection of Monoclonal Gammopathies, Both As Standalone Tests and Alongside Serum Protein Electrophoresis

Vania T M Hungria, MDPhD, Petros Kampanis, Mark T Drayson, MDPhD, Tim Plant, MD, Edvan de Queiroz Crusoe, MD MsC, Ana Lucia Peres, MD, Priscilla Cury, MD, Manuella Sampaio, MD PhD, Elyara Soares, PhD, Stephen Harding, MDPhD

Blood (2014) 124 (21): 5705.

https://doi.org/10.1182/blood.V124.21.5705.5705

Published: 2014

Journal Articles

Venous Thromboembolism Prophylaxis with Aspirin for Multiple Myeloma Patients Receiving Thalidomide Combination As First-Line Treatment

Edvan de Queiroz Crusoe, MD MsC, Mariana Massarenti, MD, Manuella Almeida, MDPhD, Priscilla Cury, MD, Fabiana Higashi, MD, Luiza Vieira, MD, Marina Rossato, MD, Ana Lucia Peres, MD, Anna Carolina Castro, MD, Ana Luiza Silva, MD, Vania T M Hungria, MDPhD

Blood (2014) 124 (21): 5764.

https://doi.org/10.1182/blood.V124.21.5764.5764

Published: 2014

NARROW

Smoldering Multiple Myeloma in Latin America- Risk Stratification

Daratumumab-Based Quadruplet Versus Triplet Induction Regimens in Frontline Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Real World Evidence- the Proportion of Myeloma Patients' Death Due to Early Progression

Variability in End-of-Life Care and Perception of Palliative Care Among Physicians in the Hematology Unit of a Reference Service in the State of Bahia, Brazil

Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS

Evaluation of Hematopoietic Stem Cell Product As a New Site for Minimal Residual Disease By Next Generation Flow in Multiple Myeloma

COVID-19 in Multiple Myeloma Patients: Frequencies and Risk Factors for Hospitalization, Ventilatory Support, Intensive Care Admission and Mortality -Cooperative Registry from Grupo Brasileiro De Mieloma Multiplo (GBRAM)

Progression Free Survival (PFS) Analysis of Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients

First Description of Upfront Target Therapy Treating AML and Bcll Presented Simultaneously As First Line

Immune Profiling Evaluation of Newly Diagnose Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients Treated with Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone. Preliminary Results

Brazilian Real-World Multiple Myeloma (MM) Electronic Platform Register Project

Preliminary Results of Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Newly Diagnosed Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients

Superiority of Triple Combination Bortezomib + Cyclophosphamide and Dexamethasone (VCD) Versus Thalidomide + Cyclophosphamide and Dexamethasone (CTD) in Newly Diagnosed Multiple Myeloma Transplant-Eligible Patients

Combined Analysis of 3,664 Patients with Multiple Myeloma (MM) from Latin America (LA) and Asia

Prevalence of Oligoclonal Bands in Multiple Myeloma Patients Who Achieved Better Results Than Very Good Partial Response after Treatment with Standard or High Doses Chemotherapy-Final Analysis

Comparison of Kappa & Lambda Freelite to Total Kappa & Lambda Immunoassays for the Detection of Monoclonal Gammopathies, Both As Standalone Tests and Alongside Serum Protein Electrophoresis

Venous Thromboembolism Prophylaxis with Aspirin for Multiple Myeloma Patients Receiving Thalidomide Combination As First-Line Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only